Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dishevelled-associated activator of morphogenesis 2 (DAAM2)
- Target
- DAAM2
- Molecular classification
- Formin-family protein, Actin-binding protein, Cytoskeletal regulator, Other (not a receptor, enzyme, transporter, or transcription factor)
01
Overview
Dishevelled-associated activator of morphogenesis 2 (DAAM2) is a member of the formin family of actin-binding proteins that mediate actin polymerization and cytoskeletal dynamics. DAAM2 binds Dishevelled proteins and participates in the Wnt/planar cell polarity (PCP) pathway, influencing the organization of the cytoskeleton. It is essential for proper myelin compaction and oligodendrocyte differentiation in the central nervous system (CNS), acting via regulation of downstream factors such as Rac1 and Gelsolin and interacting with ubiquitin ligases like Nedd4 to control actin regulator degradation. Beyond oligodendrocytes, DAAM2 is also important for astrocyte morphogenesis and thereby modulates neuron-glia interactions and circuit function. Expression of DAAM2 has been observed in various tissues (fetal and adult) and some tumors. Its deficiency or mutation may impact diseases related to myelination and glial morphology, providing a potential—but as yet unrealized—therapeutic target in demyelinating and neurological disorders.
- Other names
- DAAM2KIAA0381NPHS24dJ90A20A.1Disheveled-associated activator of morphogenesis 2
02
Mechanism of action
No drugs are reported to act directly on DAAM2. Mechanistically, modulation of DAAM2 affects the Wnt signaling pathway and cytoskeletal assembly, influencing downstream cell differentiation and myelination
03
Biological functions
Actin cytoskeleton regulationSignal transduction (through Wnt/β-catenin pathway, especially non-canonical Wnt/PCP signaling)Cell morphology and structural development (especially in oligodendrocytes and astrocytes)Myelin compaction and oligodendrocyte differentiationAstrocyte morphogenesis
04
Disease associations
Central nervous system disorders related to myelination (implicated through studies in myelin structure and white matter diseases)Potential roles in neurodevelopmental and neuropsychiatric diseases (myelin abnormalities, astrocyte dysfunction)Cancer (gene is expressed in certain tumors)
05
Safety considerations
As DAAM2 is not yet a clinical drug target, safety concerns are unknown.Targeting DAAM2 may influence cytoskeleton dynamics and myelination, suggesting potential risks in CNS development or function if therapeutically manipulated
Beyond the preview
Go deeper on Dishevelled-associated activator of morphogenesis 2 (DAAM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dishevelled-associated activator of morphogenesis 2 (DAAM2).